MLICM
TARS icon

Metropolitan Life Insurance Company (MetLife)’s Tarsus Pharmaceuticals TARS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,657
Closed -$60.2K – 1885
2024
Q1 		$60.2K Hold
1,657
– – ﹤0.01% 1316
2023
Q4 		$33.6K Hold
1,657
– – ﹤0.01% 1645
2023
Q3 		$29.4K Buy
1,657
+418
+34% +$7.4K ﹤0.01% 1690
2023
Q2 		$22.4K Hold
1,239
– – ﹤0.01% 1874
2023
Q1 		$15.6K Hold
1,239
– – ﹤0.01% 1999
2022
Q4 		$18.2K Hold
1,239
– – ﹤0.01% 2067
2022
Q3 		$21.2K Hold
1,239
– – ﹤0.01% 2000
2022
Q2 		$18.1K Buy
+1,239
New +$18.6K ﹤0.01% 2089
2021
Q1 		– Sell
-2,271
Closed -$93.9K – 2599
2020
Q4 		$93.9K Buy
+2,271
New +$64.7K ﹤0.01% 2385

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s TARS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 1,657 shares — an estimated $60.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in TARS in Q4 2020 and held it in 9 quarters. The position peaked at $93.9K in Q4 2020. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,657 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $60.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Tarsus Pharmaceuticals position peaked at $93.9K in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.